These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35214138)

  • 1. Physiologically Based Pharmacokinetic (PBPK) Model of Gold Nanoparticle-Based Drug Delivery System for Stavudine Biodistribution.
    Zazo H; Colino CI; Gutiérrez-Millán C; Cordero AA; Bartneck M; Lanao JM
    Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a multi-route physiologically based pharmacokinetic (PBPK) model for nanomaterials: a comparison between a traditional versus a new route-specific approach using gold nanoparticles in rats.
    Chou WC; Cheng YH; Riviere JE; Monteiro-Riviere NA; Kreyling WG; Lin Z
    Part Fibre Toxicol; 2022 Jul; 19(1):47. PubMed ID: 35804418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
    Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
    Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling.
    Kinvig H; Cottura N; Lloyd A; Frivold C; Mistilis J; Jarrahian C; Siccardi M
    Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):855-868. PubMed ID: 36178586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution and Physiologically-Based Pharmacokinetic Modeling of Gold Nanoparticles in Mice with Interspecies Extrapolation.
    Aborig M; Malik PRV; Nambiar S; Chelle P; Darko J; Mutsaers A; Edginton AN; Fleck A; Osei E; Wettig S
    Pharmaceutics; 2019 Apr; 11(4):. PubMed ID: 31013763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):261-75. PubMed ID: 18336055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A physiologically based pharmacokinetic model to predict pegylated liposomal doxorubicin disposition in rats and human.
    Montanha MC; Howarth A; Mohamed DA; Loier E; Main L; Rösslein M; Delmaar C; Prina-Mello A; Siccardi M
    Drug Deliv Transl Res; 2022 Sep; 12(9):2178-2186. PubMed ID: 35551629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocytosis mechanism in physiologically-based pharmacokinetic modeling of nanoparticles.
    Deng L; Liu H; Ma Y; Miao Y; Fu X; Deng Q
    Toxicol Appl Pharmacol; 2019 Dec; 384():114765. PubMed ID: 31669777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticle biodistribution coefficients: A quantitative approach for understanding the tissue distribution of nanoparticles.
    Kumar M; Kulkarni P; Liu S; Chemuturi N; Shah DK
    Adv Drug Deliv Rev; 2023 Mar; 194():114708. PubMed ID: 36682420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coupled in silico platform: Computational fluid dynamics (CFD) and physiologically-based pharmacokinetic (PBPK) modelling.
    Vulović A; Šušteršič T; Cvijić S; Ibrić S; Filipović N
    Eur J Pharm Sci; 2018 Feb; 113():171-184. PubMed ID: 29054499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of PEGylated Gold Nanoparticles: In Vitro-In Vivo Correlation.
    Dubaj T; Kozics K; Sramkova M; Manova A; Bastús NG; Moriones OH; Kohl Y; Dusinska M; Runden-Pran E; Puntes V; Nelson A; Gabelova A; Simon P
    Nanomaterials (Basel); 2022 Feb; 12(3):. PubMed ID: 35159859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically based pharmacokinetic modeling for nanoparticle toxicity study.
    Li M; Reineke J
    Methods Mol Biol; 2012; 926():369-82. PubMed ID: 22975976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An artificial intelligence-assisted physiologically-based pharmacokinetic model to predict nanoparticle delivery to tumors in mice.
    Chou WC; Chen Q; Yuan L; Cheng YH; He C; Monteiro-Riviere NA; Riviere JE; Lin Z
    J Control Release; 2023 Sep; 361():53-63. PubMed ID: 37499908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):245-59. PubMed ID: 18336054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A computational framework for interspecies pharmacokinetics, exposure and toxicity assessment of gold nanoparticles.
    Lin Z; Monteiro-Riviere NA; Kannan R; Riviere JE
    Nanomedicine (Lond); 2016 Jan; 11(2):107-19. PubMed ID: 26653715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Building in-house PBPK modelling tools for oral drug administration from literature information.
    Grandoni S; Cesari N; Brogin G; Puccini P; Magni P
    ADMET DMPK; 2019; 7(1):4-21. PubMed ID: 35350741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans.
    Hu ZY; Lu J; Zhao Y
    Br J Pharmacol; 2014 Jun; 171(11):2778-89. PubMed ID: 24471734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
    Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
    Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content.
    Li M; Panagi Z; Avgoustakis K; Reineke J
    Int J Nanomedicine; 2012; 7():1345-56. PubMed ID: 22419876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo biodistribution and physiologically based pharmacokinetic modeling of inhaled fresh and aged cerium oxide nanoparticles in rats.
    Li D; Morishita M; Wagner JG; Fatouraie M; Wooldridge M; Eagle WE; Barres J; Carlander U; Emond C; Jolliet O
    Part Fibre Toxicol; 2016 Aug; 13(1):45. PubMed ID: 27542346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.